Dr. Tolu Omokehinde is currently a Postdoctoral Research Fellow in the Center for Cancer Systems Biology, specifically in laboratory of Dr. Vito Quaranta at Vanderbilt University. He received his Ph.D. in Cancer Biology from Vanderbilt University, where his thesis focused on how breast cancer signaling, and bone dissemination of tumor cells are regulated by the interleukin-6 (IL-6) / glycoprotein 130 (gp130) cytokine family. His work centered on cytokine specific signaling pathways activated within breast cancer and novel techniques to identify tumor cells within the bone marrow of mice. Currently, Dr. Omokehinde is working with Dr. Amanda Linkous in the Quaranta lab to use 3D human embryonic stem cell-derived lung and cerebral organoids as a platform to understand small cell lung cancer (SCLC) disease progression. Combined with the assessment of subtype interactions when coupled, to longitudinal monitoring by high-content imaging or high-throughput omics data generation these models will allow us to study subtype and phenotypic transition within SCLC.